Wobenzym tablets p / o, No. 200

It is used in the complex therapy of the following diseases:

Angiology: thrombophlebitis, treatment of post-thrombophlebitic disease and acute thrombophlebitis of superficial veins, endarteritis and obliterating atherosclerosis of the arteries of the lower extremities, prevention of recurrent phlebitis, lymphatic edema.

Urology: cystitis, cystopyelitis, prostatitis, sexually transmitted infections.

Gynecology: chronic infections of the genitals, adnexitis, gestosis, mastopathy, to reduce the frequency and severity of side effects of hormone replacement therapy.

Cardiology: exertional angina, subacute stage of myocardial infarction (to improve the rheological properties of blood).

Pulmonology: sinusitis, bronchitis, pneumonia.

Gastroenterology: pancreatitis, hepatitis.

Nephrology: pyelonephritis, glomerulonephritis.

Endocrinology: diabetic angiopathy, diabetic retinopathy, autoimmune thyroiditis.

Rheumatology: rheumatoid arthritis, reactive arthritis, ankylosing spondylitis.

Dermatology: atopic dermatitis, acne.

Surgery: prevention and treatment of postoperative complications (inflammation, thrombosis, edema), adhesive disease, post-traumatic and lymphatic edema, plastic and reconstructive surgery.

Traumatology: injuries, fractures, distortions, injuries of the ligamentous apparatus, bruises, chronic post-traumatic processes, inflammation of soft tissues, burns, injuries in sports medicine.

Neurology: multiple sclerosis.

Pediatrics: atopic dermatitis, infectious and inflammatory diseases of the respiratory tract (inflammation of the upper and lower respiratory tract, pneumonia), juvenile rheumatoid arthritis, prevention and treatment of postoperative complications (suppuration and poor wound healing, adhesion formation, local edema).

Ophthalmology: Uveitis, iridocyclitis, hemophthalmus, diabetic retinopathy, ophthalmosurgery.

Wobenzym is recommended for the prevention of infectious complications and improvement of the quality of life during chemotherapy or radiation therapy. Prevention of the development of viral infections and their complications.

The tablets should be taken orally, at least 30 minutes before meals, without chewing, with water (200 ml).

Adults
Depending on the activity and severity of the disease, Wobenzym is taken in a dose of 3 to 10 tablets 3 times a day. In the first three days of taking the drug, the recommended dose is 3 tablets 3 times a day.

With an average activity of the disease, Wobenzym is prescribed in a dose of 5-7 tablets 3 times a day for 2 weeks. In the future, the dose of Wobenzym should be reduced to 3-5 tablets 3 times a day, the course is 2 weeks.

With a high activity of the disease, Wobenzym is prescribed in a dose of 7-10 tablets 3 times a day for 2-3 weeks. In the future, the dose of Wobenzym is reduced to 5 tablets 3 times a day, the course is 2-3 months.

For chronic long-term current diseases, Wobenzym can be used according to indications in courses of 3 to 6 months or more.

In order to increase the effectiveness of antibiotics and prevent dysbiosis, Wobenzym should be used throughout the course of antibiotic therapy in a dose of 5 tablets 3 times a day. After stopping the course of antibiotics to restore the microflora (biocenosis) of the intestine, Wobenzym should be prescribed 3 tablets 3 times a day for 2 weeks.

As a cover-up therapy during chemotherapy and radiation therapy, Wobenzym should be used in a dose of 5 tablets 3 times a day until the end of the course of chemotherapy and radiation therapy; to prevent infectious complications, improve the tolerability of basic therapy and improve the quality of life.

When using Wobenzym for prophylactic purposes, the dose of the drug is 3 tablets 3 times a day, the course is 1.5 months, repeated 2-3 times a year.

Children
Children from 5 to 12 years old - for 6 kg of the child's weight 1 tablet per day. From 12 years old according to the scheme for adults. The dosage and duration of treatment depends on the severity of the disease and is determined by the doctor.

1 enteric coated tablet contains:

Core:
Active ingredients:
Pancreatin 300 Prot. Unit (100.0 mg), papain 90 FIP (18.00 mg), rutoside trihydrate 50.00 mg, bromelain 225 FIP (45.00 mg), trypsin 360 FIP (12.00 mg), lipase 34 FIP Units. (10.00 mg), amylase 50 FIP Units. (10.00 mg), chymotrypsin 300 FIP (0.75 mg).

Excipients:
Lactose monohydrate 149 mg, pregelatinized starch 31.3 mg, magnesium stearate 6.00 mg, stearic acid 6.00 mg, colloidal anhydrous silicon dioxide 3.00 mg, talc 1.50 mg.

Sheath:
Film sheath 11.9 mg (methacrylic acid-methyl methacrylate copolymer (1: 1) 11.9 mg, sodium lauryl sulfate 0.04 mg), talc 4.23 mg, macrogol 6000 0.67 mg, triethyl citrate 1.20 mg , stearic acid 6.00 mg, color coating 12.8 mg (hypromellose 3.20 mg, hydroxypropyl cellulose 3.83 mg, microcrystalline cellulose 1.60 mg, glycerol 0.64 mg, talc 1.92 mg, titanium dioxide 0, 38 mg, crimson dye 4R (E 124) 0.38 mg, yellow-orange dye S (E 110) 0.83 mg).

Individual intolerance to the drug.

Diseases associated with an increased likelihood of bleeding (hemophilia, thrombocytopenia, etc.).

Hemodialysis.

Children under 5 years of age.

Trade name:

WOBENZIM

Dosage form:

Enteric-coated tablets (dragee)

Composition:

1 enteric coated tablet contains:

Core:
Active ingredients:
Pancreatin 300 Prot. Unit (100.0 mg), papain 90 FIP (18.00 mg), rutoside trihydrate 50.00 mg, bromelain 225 FIP (45.00 mg), trypsin 360 FIP (12.00 mg), lipase 34 FIP Units. (10.00 mg), amylase 50 FIP Units. (10.00 mg), chymotrypsin 300 FIP (0.75 mg).

Excipients:
Lactose monohydrate 149 mg, pregelatinized starch 31.3 mg, magnesium stearate 6.00 mg, stearic acid 6.00 mg, colloidal anhydrous silicon dioxide 3.00 mg, talc 1.50 mg.

Sheath:
Film sheath 11.9 mg (methacrylic acid-methyl methacrylate copolymer (1: 1) 11.9 mg, sodium lauryl sulfate 0.04 mg), talc 4.23 mg, macrogol 6000 0.67 mg, triethyl citrate 1.20 mg , stearic acid 6.00 mg, color coating 12.8 mg (hypromellose 3.20 mg, hydroxypropyl cellulose 3.83 mg, microcrystalline cellulose 1.60 mg, glycerol 0.64 mg, talc 1.92 mg, titanium dioxide 0, 38 mg, crimson dye 4R (E 124) 0.38 mg, yellow-orange dye S (E 110) 0.83 mg).

Description:

round, biconvex tablets with a smooth surface, from red-orange to red, with a characteristic odor.

Pharmacotherapeutic group:

anti-inflammatory, immunomodulatory agent.

ATX code:

L03AX

Pharmacological properties:

Wobenzym is a combination of natural plant and animal enzymes. Entering the body, enzymes are absorbed in the small intestine by resorption of intact molecules and, by binding to transport proteins in the blood, enter the bloodstream. Subsequently, the enzymes, migrating along the vascular bed and accumulating in the zone of the pathological process, have an immunomodulatory, anti-inflammatory, fibrinolytic, decongestant, antiplatelet and secondary analgesic effect.

Wobenzym has a positive effect on the course of the inflammatory process, limits the pathological manifestations of autoimmune and immunocomplex processes, and has a positive effect on the indicators of the body's immunological reactivity. It stimulates and regulates the level of functional activity of monocytes-macrophages, natural killer cells, stimulates antitumor immunity, cytotoxic T-lymphocytes, phagocytic activity of cells.

Under the influence of Wobenzym, the number of circulating immune complexes decreases and membrane deposits of immune complexes are removed from tissues.

Wobenzym reduces the infiltration of the interstitium by plasma cells. Increases the elimination of protein detritus and fibrin deposits in the area of ??inflammation, accelerates the lysis of toxic metabolic products and necrotic tissues.

Wobenzym normalizes the permeability of the walls of blood vessels, promotes faster resorption of hematomas and edema.

Wobenzym reduces thromboxane concentration and platelet aggregation. Regulates the adhesion of blood cells, increases the ability of erythrocytes to change their shape, regulating their plasticity, normalizes the number of normal discocytes and reduces the total number of activated forms of platelets, normalizes blood viscosity, reduces the total number of microaggregates, thus improving microcirculation and rheological properties of blood, as well as tissue supply oxygen and nutrients.

Wobenzym reduces the severity of side effects associated with the intake of hormonal drugs (hypercoagulation, etc.).

Wobenzym normalizes lipid metabolism, reduces the synthesis of endogenous cholesterol, increases the content of high density lipoproteins, lowers the level of atherogenic lipids, improves the absorption of polyunsaturated fatty acids.

Wobenzym increases the concentration of antibiotics in the blood plasma and the site of inflammation, thus increasing the effectiveness of their use. At the same time, enzymes reduce the unwanted side effects of antibiotic therapy (dysbiosis) by improving the environment.

Wobenzym regulates the mechanisms of nonspecific defense (production of interferons), thereby exhibiting antiviral and antimicrobial effects.

Indications: